Budesonide in the management of patients with Crohn's disease

Canadian Journal of Gastroenterology

Volumn 11, Issue 3, 1997, Pages 255-260

  Thomson, A B R ^a   Sadowski, Daniel ^b   Jenkins, Robert ^b   Wild, Gary ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

Budesonide; Crohn's disease; Steroid; Treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; BUDESONIDE; GLUCOCORTICOID; PREDNISOLONE; PREDNISONE;

ADRENAL FUNCTION; CROHN DISEASE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SHORT SURVEY; TIME;

EID: 0030900296     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/271653     Document Type: Short Survey

References (14)

1. Lennard-Jones JE. Sulphasalazine, corticosteroid and immunosuppressive drugs in the treatment of Crohn's disease. In: Allan RN, Keighly MRB, Alexander Williams J, Hawkins C, eds. Inflammatory Bowel Diseases. Edinburgh: Churchill Livingstone, 1985:418-27.
2. Shepherd HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. J Clin Gastroenterol 1986;8:154-9.
3. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study (NCCDS): results of treatment. Gastroenterology 1979;77:847-69.
4. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS). Results of drug treatment. Gastroenterology 1984;86:249-66.
5. Elton E, Hanauer SB. Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther 1996;110:1-22.
6. Dhaens GR, Rutgeerts PJ. How should corticosteroids be used in inflammatory bowel disease. Clin Immunother 1996;5:334-40.
7. Van Ierssel AJ, Van der Sluys Veer A, Verspaget HW, et al. Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease. Aliment Pharmacol Ther 1995;9:173-8.
8. Van Ierssel GJ, Van der Sluys Veer A, Verspaget HW, et al. Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease. Immunpharmacol 1995;29:11-7.
9. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel diseases. Can J Gastroenterol 1990;4:407-14.
10. Thiesen A, Thomson ABR. Review article: Older systemic and new topical glucocorticosteroids and the gastrointestinal tract. Aliment Pharmacol Ther 1996;10:487-96.
11. Spencer CM, McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995;150:854-72.
12. Dahlberg E, Thalen A, Brattsend R, et al. Correlation between chemical structure, receptor binding, and biological activity in some novel, highly active, 16a, 17a acetal-substinated glucocorticoids. Mol Pharmacol 1984;25:70-8.
13. Clissold SP, Heel RC. Budesonide - a preliminary review of its pharmacodynamic properties and therapeutic efficacy in severe asthma and rhinitis. Drugs 1994;28:485-518.
14. The Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991;26:1225-30.